https://www.thebodypro.com/author/myles-helfand
Myles Helfand Img

Myles Helfand

Executive Editor

Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.

Latest by Myles Helfand

COVID-19 mask profile
News

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
sizes and shapes
News

This Week in HIV Research: Many Sizes Fit Many People

Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.

By Barbara Jungwirth and Myles Helfand
reflect rethink revise
News

This Week in HIV Research: Revisiting Our Needs

Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.

By Barbara Jungwirth and Myles Helfand
MSM
News

This Week in HIV Research: Incidence and Clinical Care Trends Among MSM

Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.

By Barbara Jungwirth and Myles Helfand
BLM health care
News

This Week in HIV Research: The Long Road to Racial Health Justice

Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.

By Barbara Jungwirth and Myles Helfand
Juan Berenguer, M.D., Ph.D. and Antonio Urbina, M.D.
Interviews

Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

By Terri Wilder, M.S.W. and Myles Helfand
disparity
News

This Week in HIV Research: Disclosing Our Disparities

Sept. 17, 2020: HIV prevalence gaps between Latinx people and non-Latinx white people; Obamacare awareness and perceptions among HIV clinicians; the relationship between pain and HIV; cancer mortality trends among PLWH.

By Barbara Jungwirth and Myles Helfand
dapivirine vaginal ring
News

This Week in HIV Research: Where the Rubber Meets the Ring

Sept. 10, 2020: Concomitant use of vaginal rings with condoms; benefits of more frequent HIV screening for young MSM; Black MSM, substance use, and the PrEP continuum; HIV outcomes stratified by anti-LGTBQ policy across U.S. states.

By Barbara Jungwirth and Myles Helfand
Hep C virus
News

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
doctor with trans patient
News

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand